Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenue   $ 2,954
Operating expenses:    
Research and development $ 24,655 28,761
General and administrative 6,266 7,405
Total operating expenses 30,921 36,166
Loss from operations (30,921) (33,212)
Interest income 1,546 1,775
Interest expense (1,307) (1,217)
Change in fair value of warrant liabilities 26,974 8,865
Net loss applicable to common stockholders $ (3,708) $ (23,789)
Net loss per share applicable to common stockholders - basic $ (0.1) $ (0.85)
Net loss per share applicable to common stockholders - diluted $ (0.1) $ (0.85)
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic 38,978,046 27,842,218
Weighted-average number of common shares used in net loss per share applicable to common stockholders - diluted 38,978,046 27,842,218